vs
INDEPENDENT BANK CORP（INDB）与再鼎医药（ZLAB）财务数据对比。点击上方公司名可切换其他公司
INDEPENDENT BANK CORP的季度营收约是再鼎医药的1.7倍（$212.5M vs $127.1M），INDEPENDENT BANK CORP同比增速更快（46.9% vs 17.1%），INDEPENDENT BANK CORP自由现金流更多（$75.5M vs $-26.7M），过去两年INDEPENDENT BANK CORP的营收复合增速更高（24.3% vs 20.8%）
Independent Bank Corp是一家总部位于美国密歇根州大急流城的商业银行，业务全部布局于密歇根州内，目前在全州范围内共设有62家实体营业网点，为当地个人及企业客户提供各类银行金融服务。
再鼎医药是一家创新生物制药企业，专注于肿瘤、自身免疫性疾病、感染性疾病等领域创新疗法的研发、生产与商业化，核心市场覆盖大中华区，与全球多家头部生物科技企业合作，为存在未被满足医疗需求的患者提供治疗方案。
INDB vs ZLAB — 直观对比
营收规模更大
INDB
是对方的1.7倍
$127.1M
营收增速更快
INDB
高出29.8%
17.1%
自由现金流更多
INDB
多$102.2M
$-26.7M
两年增速更快
INDB
近两年复合增速
20.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $212.5M | $127.1M |
| 净利润 | $75.3M | — |
| 毛利率 | — | 51.0% |
| 营业利润率 | — | -54.6% |
| 净利率 | 35.5% | — |
| 营收同比 | 46.9% | 17.1% |
| 净利润同比 | 50.6% | — |
| 每股收益（稀释后） | $1.51 | $-0.05 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收INDBZLAB
| Q4 25 | $212.5M | $127.1M | ||
| Q3 25 | $203.3M | $115.4M | ||
| Q2 25 | $147.5M | $109.1M | ||
| Q1 25 | $145.5M | $105.7M | ||
| Q4 24 | $144.7M | $108.5M | ||
| Q3 24 | $141.7M | $101.8M | ||
| Q2 24 | $137.9M | $100.1M | ||
| Q1 24 | $137.4M | $87.1M |
净利润INDBZLAB
| Q4 25 | $75.3M | — | ||
| Q3 25 | $34.3M | $-36.0M | ||
| Q2 25 | $51.1M | $-40.7M | ||
| Q1 25 | $44.4M | $-48.4M | ||
| Q4 24 | $50.0M | — | ||
| Q3 24 | $42.9M | $-41.7M | ||
| Q2 24 | $51.3M | $-80.3M | ||
| Q1 24 | $47.8M | $-53.5M |
毛利率INDBZLAB
| Q4 25 | — | 51.0% | ||
| Q3 25 | — | 59.5% | ||
| Q2 25 | — | 60.6% | ||
| Q1 25 | — | 63.6% | ||
| Q4 24 | — | 61.5% | ||
| Q3 24 | — | 64.1% | ||
| Q2 24 | — | 64.9% | ||
| Q1 24 | — | 61.4% |
营业利润率INDBZLAB
| Q4 25 | — | -54.6% | ||
| Q3 25 | 21.8% | -42.3% | ||
| Q2 25 | 44.6% | -50.3% | ||
| Q1 25 | 39.3% | -53.3% | ||
| Q4 24 | — | -62.6% | ||
| Q3 24 | 39.0% | -66.6% | ||
| Q2 24 | 48.1% | -76.0% | ||
| Q1 24 | 45.5% | -80.7% |
净利率INDBZLAB
| Q4 25 | 35.5% | — | ||
| Q3 25 | 16.8% | -31.2% | ||
| Q2 25 | 34.6% | -37.3% | ||
| Q1 25 | 30.5% | -45.8% | ||
| Q4 24 | 34.6% | — | ||
| Q3 24 | 30.3% | -40.9% | ||
| Q2 24 | 37.2% | -80.2% | ||
| Q1 24 | 34.8% | -61.4% |
每股收益（稀释后）INDBZLAB
| Q4 25 | $1.51 | $-0.05 | ||
| Q3 25 | $0.69 | $-0.03 | ||
| Q2 25 | $1.20 | $-0.04 | ||
| Q1 25 | $1.04 | $-0.04 | ||
| Q4 24 | $1.18 | $-0.09 | ||
| Q3 24 | $1.01 | $-0.04 | ||
| Q2 24 | $1.21 | $-0.08 | ||
| Q1 24 | $1.12 | $-0.05 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $689.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $3.6B | $715.5M |
| 总资产 | $24.9B | $1.2B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资INDBZLAB
| Q4 25 | — | $689.6M | ||
| Q3 25 | — | $717.2M | ||
| Q2 25 | — | $732.2M | ||
| Q1 25 | — | $757.3M | ||
| Q4 24 | — | $779.7M | ||
| Q3 24 | — | $616.1M | ||
| Q2 24 | — | $630.0M | ||
| Q1 24 | — | $650.8M |
股东权益INDBZLAB
| Q4 25 | $3.6B | $715.5M | ||
| Q3 25 | $3.5B | $759.9M | ||
| Q2 25 | $3.1B | $791.7M | ||
| Q1 25 | $3.0B | $810.8M | ||
| Q4 24 | $3.0B | $840.9M | ||
| Q3 24 | $3.0B | $667.7M | ||
| Q2 24 | $2.9B | $704.2M | ||
| Q1 24 | $2.9B | $762.2M |
总资产INDBZLAB
| Q4 25 | $24.9B | $1.2B | ||
| Q3 25 | $25.0B | $1.2B | ||
| Q2 25 | $20.0B | $1.2B | ||
| Q1 25 | $19.9B | $1.2B | ||
| Q4 24 | $19.4B | $1.2B | ||
| Q3 24 | $19.4B | $985.3M | ||
| Q2 24 | $19.4B | $987.4M | ||
| Q1 24 | $19.3B | $988.4M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $78.9M | $-26.0M |
| 自由现金流经营现金流 - 资本支出 | $75.5M | $-26.7M |
| 自由现金流率自由现金流/营收 | 35.5% | -21.0% |
| 资本支出强度资本支出/营收 | 1.6% | 0.5% |
| 现金转化率经营现金流/净利润 | 1.05× | — |
| 过去12个月自由现金流最近4个季度 | $239.0M | $-158.9M |
8季度趋势，按日历期对齐
经营现金流INDBZLAB
| Q4 25 | $78.9M | $-26.0M | ||
| Q3 25 | $52.2M | $-32.0M | ||
| Q2 25 | $106.7M | $-31.0M | ||
| Q1 25 | $13.3M | $-61.7M | ||
| Q4 24 | $42.9M | $-55.8M | ||
| Q3 24 | $70.2M | $-26.8M | ||
| Q2 24 | $65.6M | $-42.2M | ||
| Q1 24 | $51.1M | $-90.1M |
自由现金流INDBZLAB
| Q4 25 | $75.5M | $-26.7M | ||
| Q3 25 | $49.7M | $-35.0M | ||
| Q2 25 | $102.5M | $-33.9M | ||
| Q1 25 | $11.3M | $-63.2M | ||
| Q4 24 | $36.5M | $-58.4M | ||
| Q3 24 | $64.4M | $-28.2M | ||
| Q2 24 | $61.9M | $-42.9M | ||
| Q1 24 | $46.7M | $-91.1M |
自由现金流率INDBZLAB
| Q4 25 | 35.5% | -21.0% | ||
| Q3 25 | 24.4% | -30.4% | ||
| Q2 25 | 69.5% | -31.1% | ||
| Q1 25 | 7.8% | -59.9% | ||
| Q4 24 | 25.2% | -53.8% | ||
| Q3 24 | 45.4% | -27.7% | ||
| Q2 24 | 44.9% | -42.9% | ||
| Q1 24 | 34.0% | -104.5% |
资本支出强度INDBZLAB
| Q4 25 | 1.6% | 0.5% | ||
| Q3 25 | 1.2% | 2.6% | ||
| Q2 25 | 2.9% | 2.6% | ||
| Q1 25 | 1.4% | 1.5% | ||
| Q4 24 | 4.4% | 2.4% | ||
| Q3 24 | 4.1% | 1.3% | ||
| Q2 24 | 2.7% | 0.7% | ||
| Q1 24 | 3.2% | 1.1% |
现金转化率INDBZLAB
| Q4 25 | 1.05× | — | ||
| Q3 25 | 1.52× | — | ||
| Q2 25 | 2.09× | — | ||
| Q1 25 | 0.30× | — | ||
| Q4 24 | 0.86× | — | ||
| Q3 24 | 1.64× | — | ||
| Q2 24 | 1.28× | — | ||
| Q1 24 | 1.07× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
INDB
暂无分部数据
ZLAB
| Zejula | $56.0M | 44% |
| Other | $21.9M | 17% |
| Nuzyra | $16.0M | 13% |
| Optune | $11.9M | 9% |
| XACDURO | $10.7M | 8% |
| Qinlock | $9.7M | 8% |
| AUGTYRO | $836.0K | 1% |
